多发性骨髓瘤免疫基因组异质性的时空评估
本研究对新诊断多发性骨髓瘤(NDMM)和复发/难治性多发性骨髓瘤(RRMM)患者进行骨髓穿刺和影像引导下相应病灶活检,分离恶性浆细胞行全外显子测序(WES),非浆细胞行下一代流式(NGF)和T细胞受体测序(TCRseq),发现髓外病变患者存在显著空间异质性,RRMM较NDMM呈显著免疫抑制,影像引导活检可检出髂骨穿刺微小残留病(MRD)阴性患者的单克隆浆细胞及第二原发恶性肿瘤。
要点
- WES显示髓外病变患者存在显著空间异质性,而髓内病变患者WES、NGF和TCRseq高度重叠。
- RRMM较NDMM呈显著免疫抑制:髓样树突状细胞、未转换记忆B细胞、Th9细胞和CD8效应记忆T细胞减少,自然杀伤细胞和调节性T细胞增多。
- 影像引导病灶活检可在髂骨穿刺MRD阴性患者中检出单克隆浆细胞及第二原发恶性肿瘤。
核心结论
- 多发性骨髓瘤存在空间异质性,髓外病变患者WES显示显著空间异质性;影像引导病灶活检具有临床意义。
研究设计与样本
- 对新诊断多发性骨髓瘤(NDMM)和复发/难治性多发性骨髓瘤(RRMM)患者行骨髓穿刺和影像引导下相应病灶活检。
- 分离浆细胞行全外显子测序(WES),非浆细胞行下一代流式(NGF)和T细胞受体测序(TCRseq)。
主要发现
- 髓内病变患者WES、NGF和TCRseq高度重叠,髓外病变患者WES显示显著空间异质性。
- RRMM较NDMM呈显著免疫抑制:髓样树突状细胞、未转换记忆B细胞、Th9细胞和CD8效应记忆T细胞减少,自然杀伤细胞和调节性T细胞增多。
- RRMM较NDMM和健康个体检出的T细胞受体(TCR)序列更少。
- 诱导治疗后TCR库丰富度增至健康个体水平,NGF显示调节性T细胞和髓样抑制细胞增多,与缓解深度无关。
- 影像引导病灶活检可在髂骨穿刺MRD阴性患者中检出单克隆浆细胞,并在MRD阴性患者中识别第二原发恶性肿瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spatial heterogeneity is a common phenomenon in metastatic solid tumors and an evolving concept in multiple myeloma (MM). The interplay between malignant plasma cells (PCs) and the microenvironment has not yet been analyzed in MM. For this purpose, we performed bone marrow aspirates and imaging-guided biopsies of corresponding lesions in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM) patients. PCs were isolated and subjected to whole-exome sequencing (WES). Non-PCs were studied with next-generation flow (NGF) and T-cell receptor sequencing (TCRseq) to analyze the connection between malignant and nonmalignant cells in the bone marrow and in lesions. Although we observed a strong overlap from WES, NGF, and TCRseq in patients with intramedullary disease, WES revealed significant spatial heterogeneity in patients with extramedullary disease. NGF showed significant immunosuppression in RRMM compared with NDMM as indicated by fewer myeloid dendritic cells, unswitched memory B cells, Th9 cells, and CD8 effector memory T cells but more natural killer and regulatory T cells. Additionally, fewer T-cell receptor (TCR) sequences were detected in RRMM compared with NDMM and healthy individuals. After induction therapy, TCR repertoire richness increased to levels of healthy individuals, and NGF showed more regulatory T cells and myeloid-derived suppressor cells, regardless of depth of response. Clinical significance of imaging-guided biopsies of lesions was demonstrated by detection of monoclonal PCs in patients without measurable residual disease (MRD) in aspirates from the iliac crest as well as identification of secondary primary malignancies in MRD- patients. Furthermore, site-specific clones with different drug susceptibilities and genetically defined high-risk features were detected by our workflow.
引用
- Merz M, Hu Q, Merz AMA, et al. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023. PMID: 35868022. doi:10.1182/bloodadvances.2022007457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。